Correction to: British Journal of Cancer (2013) 109, 60–67; doi:10.1038/bjc.2013.226
Since the advance online publication of this paper in May 2013, the authors realised that fresh calculations of the cohort of testicular cancer patients were required after omitting nine patients who received radiotherapy. This resulted in slightly incorrect numbers presented in the data displayed in Tables 2, 4 and 5, and in sections of the Results.
Table 2. Characteristics of GCT survivors according to treatment group and of healthy subjects.
| Treatment groups | |||||||
|---|---|---|---|---|---|---|---|
|
Parameters |
Healthy subjects N=360) |
Surgery (N=58) |
Carboplatin (N=21) |
Combination CT (N=176) |
All survivors (N=255) |
P-valuea |
P-valueb |
|
Demographics mean±s.d., median (min–max) | |||||||
| Age at diagnosis (years) |
NA |
30.4±8.3 28.9 (20.0–61.9) |
37.6±12.2 33.8 (24.8–50.6) |
31.2±8.8 29.6 (14.2–54.2) |
31.4±8.7 29.8 (14.2–61.9) |
∼ |
∼ |
| Age at blood analysis (years) |
43.1±14.6 44.0 (18–70) |
36.6±10.4 36.5 (20.1–69.5) |
42.1±12.0 39.3 (26.8–57.4) |
38.7±10.9 38.7 (18.2–63.4) |
39.2±10.7 38.3 (18.2–69.5) |
NS |
NS |
| Interval between curative treatment and blood analysis (years) |
NA |
6.2±6.7 3.2 (0.1–2) |
4.5±3.5 3.1 (0.7–13.2) |
8.8±7.8 6.3 (0.6–30.2) |
7.8±7.4 5.0 (0.1–30.2) |
∼ |
∼ |
|
Clinical characteristics: median (min–max) | |||||||
| Body weight (kg) |
85 (54–138) |
82 (60–138) |
83 (64–132) |
85 (60–126) |
84 (60–138) |
0.005 |
0.01 |
| Height (m) |
1.80 (1.57–2.06) |
1.85 (1.65–1.99) |
1.83 (1.69–1.98) |
1.83 (1.65–2.01) |
1.83 (1.65–2.01) |
0.006 |
<0.001 |
| Body mass index (kg m−2) |
25.8 (19.5–42.6) |
24.2 (16.8–38.5) |
25.0 (20.5–35.8) |
25.6 (18.4–36.4) |
25.5 (16.8–38.5) |
NS |
0.01 |
| Waist circumference (cm) |
94 (74–130) |
92 (85–134) |
96 (81–137) |
96 (67–124) |
96 (67–137) |
<0.001 |
0.003 |
| Systolic blood pressure (mm Hg)c |
130 (110–200) |
122 (95–185) |
130 (90–155) |
126 (90–200) |
125 (90–200) |
NS |
0.006 |
| Diastolic blood pressure (mm Hg)c |
80 (62–110) |
80 (54–110) |
80 (65–90) |
80 (53–114) |
80 (53–114) |
NS |
NS |
| Creatinine clearance (Cockroft formula; ml min−1) | 122 (84–205) | 120 (70–165) | 123 (56–217) | 122 (56–217) | ∼ | ∼ | |
Abbreviations: CT=chemotherapy; GCT=germ cell tumour; NA=not applicable; NS=not significant.
P-value for comparison between values of combination-CT survivors and healthy subjects (independent-samples Student's t-test or independent-samples Mann–Whitney where appropriate).
P-value for comparison between values of all survivors and healthy subjects (independent-samples Student's t-test or independent-samples Mann–Whitney where appropriate).
Systolic and diastolic blood pressure measurements for survivors treated with anti-hypertensive medication are excluded.
Table 4. Prevalence of metabolic syndrome according to NCEP-ATPIII (upper part) and IDF criteria (lower part) in survivors and in healthy subjects.
| Treatment groups | |||||||
|---|---|---|---|---|---|---|---|
|
Parameters ℰ𝒩𝒯ℐ𝒯𝒴𝒮𝒯𝒜ℛ𝒯ℰ𝒩𝒯ℐ𝒯𝒴ℰ𝒩𝒟 |
Healthy subjects (N=360) |
Surgery (N=57a |
Carboplatin (N=20a |
Combination CT (N=174a |
Survivors (N=251a |
Combination CT, OR (95% CI)b |
Survivors OR (95% CI)c |
|
According to NCEP-ATP III | |||||||
| Hypertension | 81 (22.5) | 8 (14.0) | 4 (20.0) | 53 (31.0) | 66 (26.3) | 1.6 (1.0–2.3) | 1.2 (0.8–1.8) |
| Obesity | 70 (19.4) | 10 (17.5) | 6 (30.0) | 51 (29.3) | 67 (26.7) | 1.7 (1.1–2.6) | 1.5 (1.0–2.2) |
| Insulin resistance | 16 (4.4) | 2 (3.5) | 1 (5.0) | 11 (6.3) | 14 (5.6) | 1.5 (0.7–3.2) | 1.3 (0.6–2.7) |
| Dyslipidemiad | 36 (10.0) | 7 (12.3) | 4 (20.0) | 35 (20.1) | 46 (18.3) | 2.3 (1.4–3.8) | 2.0 (1.3–3.2) |
| Hypertriglyceridemiad | 84 (23.3) | 13 (22.8) | 6 (30.0) | 61 (35.1) | 80 (31.9) | 1.8 (1.2–2.6) | 1.5 (1.1–2.2) |
| Metabolic syndrome |
29 (8.1) |
5 (8.8) |
2 (10.0) |
29 (16.7) |
36 (14.3) |
2.3 (1.3–4.0) |
1.9 (1.1–3.2) |
|
According to IDF | |||||||
| Hypertension | 170 (47.2) | 21 (36.8) | 8 (40.0) | 83 (47.7) | 112 (44.6) | 1.0 (0.7–1.5) | 0.9 (0.7–1.2) |
| Obesity | 165 (45.8) | 24 (42.1) | 13 (65.0) | 107 (61.5) | 144 (57.4) | 1.9 (1.3–2.7) | 1.6 (1.1–2.2) |
| Insulin resistance | 57 (15.8) | 6 (10.5) | 3 (15.0) | 34 (19.5) | 43 (17.1) | 1.3 (0.8–2.1) | 1.1 (0.7–1.7) |
| Dyslipidemiad | 36 (10.0) | 7 (12.3) | 4 (20.0) | 35 (20.1) | 46 (18.3) | 2.3 (1.4–3.8) | 2.0 (1.3–3.2) |
| Hypertriglyceridemiad | 84 (23.3) | 13 (22.8) | 6 (30.0) | 61 (35.1) | 80 (31.9) | 1.8 (1.2–2.6) | 1.5 (1.1–2.2) |
| Metabolic syndrome | 59 (16.4) | 9 (15.8) | 5 (25.0) | 52 (29.9) | 66 (26.3) | 2.2 (1.4–3.3) | 1.8 (1.2–2.7) |
Abbreviations: CT=chemotherapy; CI=confidence interval; GCT=germ cell tumour; IDF=International Diabetes Federation; OR=odds ratio; NCEP-ATPIII=National Cholesterol Education Program Adult Treatment Panel III 2001.
Four survivors diagnosed with diabetes mellitus before orchidectomy (N=1), single-dose carboplatin (N=1), or combination CT (N=2) are excluded in this table.
OR for risk stratification between healthy subjects and combination CTsurvivors.
OR for risk stratification between healthy subjects and all GCT survivors.
Prevalence of dyslipidemia and hypertriglyceridemia are similar according to NCEP-ATPIII and IDF criteria.
Table 5. Metabolic syndrome prevalence and odds ratio's in four cross-sectional studies.
| Parameters | Nuver et al (2005) | Haugnes et al (2007) | Wethal et al (2007) | this study | ||
|---|---|---|---|---|---|---|
| Number of survivors | 130 | 1135 | 589 | 251 | ||
| Mean age (years) (range) | 38.5 (20–65) | 42.5 (23–60) | 42 (23–60) | 39.6 (18–70) | ||
| Mean follow-up time (years) (range) | 7.5 (3–13) | 11.2 (5–22) | 11 (7.7–14.5) | 7.8 (0.1–30.0) | ||
| Healthy subjects (N) | 47 | 1150 | 8835 | 360 | ||
| Metabolic syndrome definition |
NCEP-ATP III |
Modified NCEP-ATP III ⩾ 2 criteriaa |
Modified NCEP-ATP III ⩾3 criteriaa |
Modified criteria ⩾3 criteriaa |
NCEP-ATP III |
IDF |
|
Metabolic syndrome prevalence (%) | ||||||
| All GCT survivors | 38 (29.2) | 447 (39.4) | 92 (8.1) | 82 (13.9) | 36 (14.3) | 66 (26.3) |
| Combination CT | 22 (25.6) | 191 (41.2) | 40 (8.6) | 38 (17.4) | 29 (16.7) | 52 (29.9) |
| Single-dose carboplatin | ∼ | ∼ | ∼ | ∼ | 2 (10.0) | 5 (25.0) |
| Radiotherapy | ∼ | 184 (42.0) | 37 (8.3) | 35 (15.2) | ∼ | ∼ |
| Surgery only | 16 (34.0) | 72 (33.0) | 15 (6.7) | 9 (6.4) | 5 (8.8) | 9 (15.8) |
| Healthy subjects |
4 (8.5) |
584 (51.5) |
170 (14.8) |
Not mentioned |
29 (8.1) |
59 (16.4) |
|
OR (95% CI) adjustmentsb | ||||||
| GCT survivors vs healthy subjects | 4.4 (1.5–13.2) | 0.6 (0.5–0.7) | 0.5 (0.4–0.7) | ∼ | 1.9 (1.1–3.2) | 1.8 (1.2–2.7) |
| Combination CT vs healthy subjects | 3.7 (1.2–11.5) | 0.7 (0.5–0.8) | 0.5 (0.4–0.8) | 3.7 (1.5–9.1) | 2.3 (1.3–4.0) | 2.2 (1.4–3.3) |
| Combination chemotherapy vs surgery only | 0.6 (0.3–1.3) | 1.5 (1.1–2.1) | 1.3 (0.7–2.4) | 3.1 (1.4–6.6) | 2.1 (0.8–5.7) | 2.3 (1.0–5.0) |
Abbreviations: CI=confidence interval; CT=chemotherapy; GCT=germ cell tumour; IDF=International Diabetes Federation; OR=Odds ratio; NCEP-ATPIII=National Cholesterol Education Program Adult Treatment Panel III 2001.
Non-fasting blood samples.
Calculated from the raw data presented in the individual reports.
In order to present the results correctly moving forward, the data have now been corrected in the paper which appears in this issue and are represented in the Tables following (see below).